Cannara Biotech Profit Margin

The latest profit margin for LOVFF is 9.22% as of May 2026. That compares with 15.21% in the prior-year period — down 39.4% year over year. That is below the sector sector average of 13.23%. Investors often review this figure alongside Cannara Biotech's historical trend and sector peers before judging valuation or financial health.

Over the past year, LOVFF's profit margin moved from 15.21% to 9.22% — a 39.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Cannara Biotech's valuation or profitability profile.

Against its sector companies, LOVFF currently prints 9.22% for profit margin, while the sector average sits near 13.23%. That is roughly 30.3% below the sector mean. Large gaps often invite a closer look at Cannara Biotech's growth, margins, and balance sheet.

Profit Margin shows how effectively Cannara Biotech converts resources into returns. At 9.22%, LOVFF may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 15.21% in the prior-year period — down 39.4% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting LOVFF's profit margin (9.22%), review year-over-year change from 15.21%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.